Technical Analysis for NCNA - NuCana plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical NCNA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Slingshot Bearish | Bearish Swing Setup | 2.04% | |
| Stochastic Buy Signal | Bullish | 2.04% | |
| Calm After Storm | Range Contraction | 2.04% | |
| Lower Bollinger Band Walk | Weakness | 2.04% | |
| Oversold Stochastic | Weakness | 2.04% | |
| Calm After Storm | Range Contraction | 8.46% | |
| Lower Bollinger Band Walk | Weakness | 8.46% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| 60 Minute Opening Range Breakout | about 5 hours ago | |
| Down 1% | about 7 hours ago | |
| Up 2% | about 7 hours ago | |
| Up 1% | about 7 hours ago | |
| 10 DMA Resistance | 1 day ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/19/2020
- Sector: Healthcare
- Industry: Biotechnology
NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline of products includes Acelarin, NUC-3373 and NUC-7738. Acelarin is a nucleotide analog and is a ProTide transformation of gemcitabine for the treatment of cancer. The Company is evaluating Acelarin in four clinical trials across several solid tumor indications. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil for the treatment of a wide range of cancers. NUC-3373 is in a Phase I trial for the potential treatment of a wide range of solid tumor cancers. NUC-7738 is a ProTide transformation of cordycepin, a novel nucleoside analog.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 10.59 |
| 52 Week Low | 3.81 |
| Average Volume | 251,128 |
| 200-Day Moving Average | 5.64 |
| 50-Day Moving Average | 5.46 |
| 20-Day Moving Average | 5.27 |
| 10-Day Moving Average | 5.07 |
| Average True Range | 0.38 |
| ADX | 13.51 |
| +DI | 19.79 |
| -DI | 20.63 |
| Chandelier Exit (Long, 3 ATRs ) | 4.76 |
| Chandelier Exit (Short, 3 ATRs ) | 5.64 |
| Upper Bollinger Band | 5.98 |
| Lower Bollinger Band | 4.55 |
| Percent B (%b) | 0.31 |
| BandWidth | 27.09 |
| MACD Line | -0.19 |
| MACD Signal Line | -0.14 |
| MACD Histogram | -0.0557 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.34 | ||||
| Resistance 3 (R3) | 5.31 | 5.17 | 5.28 | ||
| Resistance 2 (R2) | 5.17 | 5.08 | 5.18 | 5.26 | |
| Resistance 1 (R1) | 5.08 | 5.03 | 5.13 | 5.11 | 5.24 |
| Pivot Point | 4.94 | 4.94 | 4.96 | 4.96 | 4.94 |
| Support 1 (S1) | 4.86 | 4.86 | 4.90 | 4.89 | 4.76 |
| Support 2 (S2) | 4.72 | 4.80 | 4.73 | 4.74 | |
| Support 3 (S3) | 4.63 | 4.72 | 4.72 | ||
| Support 4 (S4) | 4.66 |
